Company Filing History:
4 out of 6 
2 out of 18 
1 out of 75 
Years Active: 2000-2025
Title: The Innovative Mind of Thomas Blankenstein
Introduction
Thomas Blankenstein is a prominent inventor based in Berlin, Germany. He has made significant contributions to the field of medical science, especially in cancer therapy, with a remarkable portfolio of nine patents. His innovative work focuses on high avidity antigen recognizing constructs, which have promising applications in the diagnosis and treatment of various cancers.
Latest Patents
Among his latest patents, Blankenstein has developed constructs that specifically target the melanoma-associated antigen (MAGE) A1. These novel high avidity antigen recognizing constructs provide new opportunities for the diagnosis, prevention, or therapy of tumorous diseases that uniquely express the MAGE-A1 antigen. Additionally, he has invented high avidity T-cell receptors that recognize Human Papilloma Virus (HPV) antigens. This innovation is vital for diagnosing and treating HPV infections and their associated cancers, including cervical, nasopharyngeal, or head and neck cancer. His inventions also involve nucleic acids, vectors, and recombinant cells that express these significant proteins.
Career Highlights
Blankenstein's career has been marked by his association with esteemed research institutions. He has worked at the Max Delbrück Center for Molecular Medicine and the Helmholtz Zentrum München, which is part of the German Research Center for Health and Environment. His research at these institutions has propelled advancements in immune therapy, particularly in developing adoptive T cell therapies for cancer treatment.
Collaborations
Throughout his career, Blankenstein has collaborated with notable scientists, including Matthias Obenaus and Jehad Charo. These collaborations have further enriched his research contributions and have played a significant role in fostering innovation within the field of cancer biology.
Conclusion
Thomas Blankenstein's innovative spirit and dedication to advancing medical science are evident in his extensive patent portfolio and collaborative efforts. His pioneering work in high avidity antigen recognizing constructs represents significant strides toward effective cancer therapies, impacting many lives. As he continues to explore the possibilities within this domain, the scientific community eagerly anticipates his future contributions.